This study aims to comprehensively identify the various treatment patterns of second- or subsequent-line palliative chemotherapy used in patients with metastatic colorectal cancer who have experienced failure of first-line palliative chemotherapy and to evaluate the prognosis of each treatment.
Patients who have signed the informed consent after receiving information about the purpose and method of this study.
Patients with histologically and radiologically confirmed metastatic colorectal cancer (colorectal cancer) who have evaluable (measurable) lesions.
Patients scheduled to receive their first second-line palliative chemotherapy following failure of first-line palliative chemotherapy (including those who relapse during or within 6 months after completion of postoperative adjuvant therapy, necessitating palliative chemotherapy).
Patients who understand the research, are cooperative in the research process, and are deemed capable of participating until the completion date.
Female patients who are pregnant, have childbearing potential, or are breastfeeding.
Has received an investigational product within 4 weeks from the study enrollment or has plans to participate in another clinical trial during the participation of this study.
Other subjects who are considered inappropriate to participate in this study by the judgment of the investigator.